Tirzepatide (20mg)

Tirzepatide is a weight management peptide that activates two hunger and metabolism receptors at once — GLP-1 and GIP. Most people are familiar with semaglutide (Ozempic, Wegovy), which activates GLP-1 alone. Tirzepatide does more by adding the GIP signal on top, and the results in clinical trials have been consistently stronger — up to 22.5% body weight reduction over 72 weeks. It's the compound that raised the bar before Retatrutide arrived.

Semaglutide (Ozempic/Wegovy) activates one receptor — GLP-1. Tirzepatide activates two: GLP-1 and GIP. The GIP signal adds another layer of appetite and metabolic control that semaglutide doesn't have. In head-to-head research, Tirzepatide has consistently outperformed semaglutide on weight loss outcomes — which is why it's become the benchmark in this category. If you're comparing them: Tirzepatide is the stronger dual option; Retatrutide goes one step further with a third receptor.

Tirzepatide sends two signals your body responds to naturally — it's just sending them together, and at greater intensity. The GLP-1 signal slows digestion so you feel full longer, reduces appetite through the brain, and improves how your body responds to insulin after eating. The GIP signal adds improved fat metabolism and insulin sensitivity on top. The combined effect is less hunger, better blood sugar control, and more body fat being used as fuel — all at once.

Phase 3 SURMOUNT trial data showed mean body weight reductions of up to 22.5% over 72 weeks — one of the largest figures ever recorded in clinical weight management research. Participants also saw meaningful improvements in fasting blood glucose, HbA1c, waist circumference, and cardiometabolic markers. That data is what established Tirzepatide as the dual-agonist benchmark, and the standard newer compounds like Retatrutide are now being compared against.

Tirzepatide activates two receptors: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and glucagon. That third glucagon signal is what sets Retatrutide apart — it directly increases how much energy your body burns, which Tirzepatide doesn't do. Early Retatrutide trials have shown even greater fat loss results. Think of Tirzepatide as the proven dual-agonist option, and Retatrutide as where the research has gone next.

Tirzepatide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Tirzepatide vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

Tirzepatide (20mg) will be available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia, reducing delays linked to international freight and customs processing. Batch-specific Certificate of Analysis access will be available in our CoA library.

Tirzepatide (20mg) is currently in stock at Aussie Peptides and available for domestic dispatch across Australia. Tirzepatide (20mg) is priced at $199.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.

Once restocked, ordering is straightforward — add Tirzepatide (20mg) to your cart on the Aussie Peptides website and complete checkout through our secure payment system. All orders are fulfilled domestically and shipped with tracking to any address across Australia.